Total Payments
$51,246
2024 Payments
$160.95
Companies
15
Transactions
56
Medicare Patients
1,761
Medicare Billing
$885,713
Payment Breakdown by Category
Other$34,125 (66.6%)
Consulting$12,158 (23.7%)
Travel$3,789 (7.4%)
Food & Beverage$1,174 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,125 | 14 | 66.6% |
| Consulting Fee | $12,158 | 5 | 23.7% |
| Travel and Lodging | $3,789 | 12 | 7.4% |
| Food and Beverage | $1,174 | 25 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $49,240 | 39 | $0 (2018) |
| Baxter Healthcare | $862.00 | 1 | $0 (2021) |
| C. R. Bard, Inc. & Subsidiaries | $355.83 | 1 | $0 (2020) |
| Vifor Pharma, Inc. | $200.00 | 1 | $0 (2021) |
| GlaxoSmithKline, LLC. | $140.00 | 1 | $0 (2023) |
| Zimmer Biomet Holdings, Inc. | $124.49 | 1 | $0 (2021) |
| Amgen Inc. | $110.65 | 4 | $0 (2024) |
| Ceribell, Inc. | $53.05 | 1 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $31.14 | 1 | $0 (2022) |
| Sandoz Inc. | $25.44 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $160.95 | 5 | Amgen Inc. ($61.68) |
| 2023 | $192.01 | 3 | GlaxoSmithKline, LLC. ($140.00) |
| 2022 | $45.36 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($31.14) |
| 2021 | $1,209 | 4 | Baxter Healthcare ($862.00) |
| 2020 | $374.82 | 2 | C. R. Bard, Inc. & Subsidiaries ($355.83) |
| 2018 | $22,549 | 10 | Merck Sharp & Dohme Corporation ($22,549) |
| 2017 | $26,715 | 30 | Merck Sharp & Dohme Corporation ($26,691) |
All Payment Transactions
56 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Nephrology | ||||||
| 12/04/2024 | Ceribell, Inc. | POCKET EEG DEVICE (Device) | Food and Beverage | Cash or cash equivalent | $53.05 | General |
| Category: Neurology | ||||||
| 09/11/2024 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $34.98 | General |
| Category: Nephrology | ||||||
| 07/25/2024 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $26.70 | General |
| Category: Nephrology | ||||||
| 05/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Cardio-renal | ||||||
| 11/30/2023 | Amgen Inc. | Parsabiv (Drug), TAVNEOS | Food and Beverage | In-kind items and services | $26.57 | General |
| Category: Nephrology | ||||||
| 08/16/2023 | Sandoz Inc. | — | Food and Beverage | In-kind items and services | $25.44 | General |
| 05/22/2023 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Consulting Fee | Cash or cash equivalent | $140.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/28/2022 | Fresenius USA Marketing, Inc. | Velphoro (Drug), KORSUVA | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: Phosphate binder for ESRD | ||||||
| 11/01/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $31.14 | General |
| Category: DIABETES | ||||||
| 12/03/2021 | Amgen Inc. | Parsabiv (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Nephrology | ||||||
| 11/22/2021 | Baxter Healthcare | Renal - Revaclear (Device) | Consulting Fee | Cash or cash equivalent | $862.00 | General |
| Category: Renal | ||||||
| 04/06/2021 | Zimmer Biomet Holdings, Inc. | Stratum Foot Plating System (Device) | Food and Beverage | In-kind items and services | $124.49 | General |
| Category: Foot & Ankle | ||||||
| 01/04/2021 | Vifor Pharma, Inc. | Veltassa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| Category: Hyperkalemia | ||||||
| 11/05/2020 | C. R. Bard, Inc. & Subsidiaries | — | Consulting Fee | Cash or cash equivalent | $355.83 | General |
| 04/02/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/12/2018 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,505.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/01/2018 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,505.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/16/2018 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,505.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/14/2018 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,505.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/29/2018 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,505.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/26/2018 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,505.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/25/2018 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,505.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/22/2018 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,505.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/19/2018 | Merck Sharp & Dohme Corporation | ZEPATIER (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,505.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 370 | 878 | $644,180 | $173,226 |
| 2022 | 8 | 385 | 970 | $662,910 | $178,018 |
| 2021 | 9 | 507 | 1,349 | $974,070 | $270,800 |
| 2020 | 11 | 499 | 1,417 | $1.0M | $263,669 |
Total Patients
1,761
Total Services
4,614
Medicare Billing
$885,713
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 55 | 381 | $426,720 | $121,194 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 39 | 71 | $41,180 | $10,525 | 25.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 70 | 131 | $39,300 | $10,120 | 25.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 101 | $43,430 | $9,785 | 22.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 39 | 65 | $26,650 | $7,379 | 27.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 33 | 33 | $26,400 | $5,414 | 20.5% |
| 90937 | Hemodialysis procedure requiring repeated evaluation | Facility | 2023 | 45 | 58 | $23,780 | $5,243 | 22.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $10,560 | $2,284 | 21.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 14 | 22 | $6,160 | $1,281 | 20.8% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 54 | 372 | $416,640 | $120,273 | 28.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 119 | $51,170 | $12,313 | 24.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 60 | 62 | $49,600 | $11,802 | 23.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 78 | 169 | $50,700 | $11,192 | 22.1% |
| 90937 | Hemodialysis procedure requiring repeated evaluation | Facility | 2022 | 47 | 83 | $34,030 | $7,770 | 22.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 46 | 77 | $31,570 | $7,761 | 24.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 39 | 76 | $21,280 | $5,008 | 23.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $7,920 | $1,898 | 24.0% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 77 | 579 | $648,480 | $193,098 | 29.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 50 | 129 | $55,620 | $14,372 | 25.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 69 | 76 | $60,800 | $13,267 | 21.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 93 | 189 | $56,700 | $12,557 | 22.1% |
| 90937 | Hemodialysis procedure with repeated evaluations | Facility | 2021 | 63 | 106 | $43,460 | $10,112 | 23.3% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 62 | 137 | $38,360 | $8,883 | 23.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 57 | 89 | $36,490 | $8,437 | 23.1% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 21 | 24 | $22,560 | $6,671 | 29.6% |
About Dr. Steven Smith, M.D
Dr. Steven Smith, M.D is a Nephrology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1881689222.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Smith, M.D has received a total of $51,246 in payments from pharmaceutical and medical device companies, with $160.95 received in 2024. These payments were reported across 56 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($34,125).
As a Medicare-enrolled provider, Smith has provided services to 1,761 Medicare beneficiaries, totaling 4,614 services with total Medicare billing of $885,713. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location New York, NY
- Active Since 09/13/2005
- Last Updated 05/14/2019
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1881689222
Products in Payments
- ZEPATIER (Drug) $38,140
- Renal - Revaclear (Device) $862.00
- Veltassa (Drug) $200.00
- BENLYSTA (Biological) $140.00
- Stratum Foot Plating System (Device) $124.49
- Parsabiv (Drug) $110.65
- POCKET EEG DEVICE (Device) $53.05
- JARDIANCE (Drug) $31.14
- Kerendia (Drug) $24.52
- RENVELA (Drug) $23.55
- TARPEYO (Drug) $21.70
- LOKELMA (Drug) $18.99
- Velphoro (Drug) $14.22
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in New York
Dr. Gerald Appel, M.d, M.D
Nephrology — Payments: $842,842
Nephrology $842,842
Dr. Richard Chan, Md, MD
Nephrology — Payments: $525,489
Nephrology $525,489
Dr. Steven Coca, D.o., M.s, D.O., M.S
Nephrology — Payments: $388,012
Nephrology $388,012
Dr. Jai Radhakrishnan, M.d, M.D
Nephrology — Payments: $243,935
Nephrology $243,935
Dr. David Bernard, Md, MD
Nephrology — Payments: $235,726
Nephrology $235,726
Dr. Girish Nadkarni, Md, MD
Nephrology — Payments: $217,113
Nephrology $217,113